title: Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease.
abstract: BACKGROUND
  There is evidence that iron may play a role in the pathology of Alzheimer's disease (AD). There may be genetic factors that contribute to iron deposition resulting in tissue damage thus exacerbating AD.
  
  
  METHODS
  We have genotyped 269 healthy elderly controls, 191 cases with definite or probable AD, and 69 with mild cognitive impairment (MCI) from the OPTIMA cohort.
  
  
  RESULTS
  We have examined the interaction between the C2 variant of the transferrin (TF) gene and the C282Y allele of the haemochromatosis (HFE) gene as risk factors for developing AD. Our results showed that each of the two variants was associated with an increased risk of AD only in the presence of the other. Neither allele alone had any effect. Carriers of both variants were at 5 times greater risk of AD compared with all others. The interaction was significant by logistic regression (p = 0.014) and by synergy factor analysis (p = 0.015, synergy factor = 5.1). Further, carriers of these two alleles plus apolipoprotein E epsilon4 (APOE4) were at still higher risk of AD: of the 14 tri-carriers of the three variants, identified in this study, 12 had AD and two MCI.
  
  
  CONCLUSIONS
  We suggest that the combination of TF C2 and HFE C282Y may lead to an excess of redox-active iron and the induction of oxidative stress in neurones, which is exacerbated in carriers of APOE4. Since 4% of Northern Europeans carry the two iron-related variants and since iron overload is a treatable condition, these results merit replication.
authors.affiliation: MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK. kathryn.robson@imm.ox.ac.uk
authors.forename: K J H
authors.initials: KJ
authors.lastname: Robson
authors.forename: D J
authors.initials: DJ
authors.lastname: Lehmann
authors.forename: V L C
authors.initials: VL
authors.lastname: Wimhurst
authors.forename: K J
authors.initials: KJ
authors.lastname: Livesey
authors.forename: M
authors.initials: M
authors.lastname: Combrinck
authors.forename: A T
authors.initials: AT
authors.lastname: Merryweather-Clarke
authors.forename: D R
authors.initials: DR
authors.lastname: Warden
authors.forename: A D
authors.initials: AD
authors.lastname: Smith
mesh_terms: D000368:Aged; D000483:Alleles; D000544:Alzheimer Disease / Q000235:genetics* / Q000378:metabolism; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D018384:Oxidative Stress; D011110:Polymorphism, Genetic; D014168:Transferrin / Q000235:genetics* / Q000378:metabolism
chemical_list: D053327:Apolipoprotein E4; D001057:Apolipoproteins E; C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D014168:Transferrin; D007501:Iron